Jan 09, 2025
The GLP-1 drug landscape, known for significant potential in weight reduction, has seen a 250% rise in prescriptions since early 2022. This increase reflects both public interest and the therapeutic benefits of these medications. In December 2024, Zepbound received FDA approval for treating obstructive sleep apnea (OSA). However, it’s been determined that Zepbound will not be covered for this new indication.
The decision not to cover Zepbound for treating OSA is grounded in an analysis of its efficacy. The effectiveness of Zepbound in alleviating OSA symptoms is primarily due to weight loss, not a direct pharmacological action on the disorder. Clinical evidence supports that the significant weight reduction facilitated by Zepbound can improve OSA symptoms, as obesity is a major risk factor for this condition.
Anthem continues to evaluate emerging clinical evidence and other potential indications for GLP-1 drugs, and they remain committed to making decisions that best serve our clients and members.
We are committed to keeping you informed - stay connected with your Amwins Connect team for important Anthem updates.
